<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04986085</url>
  </required_header>
  <id_info>
    <org_study_id>GETNE-S2109</org_study_id>
    <nct_id>NCT04986085</nct_id>
  </id_info>
  <brief_title>Nutrition in Gastroenteropancreatic Neuroendocrine Tumor</brief_title>
  <acronym>NUTRIGETNE</acronym>
  <official_title>Nutritional Status of Patients With Gastroenteropancreatic Neuroendocrine Tumors in Spain: NUTRIGETNE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol de Tumores Neuroendocrinos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Espanol de Tumores Neuroendocrinos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is well known that the prevalence of malnutrition or risk of malnutrition in cancer&#xD;
      patients is high, as well as its impact on different parameters such as hospitalization,&#xD;
      survival or response to certain treatments. In patients with gastroenteropancreatic (GEP)&#xD;
      neuroendocrine tumors (NET), due to their heterogeneity and longer survival, it is expected&#xD;
      that the prevalence of malnutrition is probably underdiagnosed, as well as the existence of a&#xD;
      negative impact on different parameters (quality of life, survival). So far, the studies&#xD;
      carried out on nutrition and NET are very scarce and none has been carried out so far in&#xD;
      Spain.&#xD;
&#xD;
      Before being able to carry out nutritional intervention studies on these patients, it is&#xD;
      necessary to know the reality of the nutritional status of patients with NETs in Spain. The&#xD;
      main motivation for the NUTRIGETNE study is to evaluate the epidemiological status of&#xD;
      nutrition in NETs in the spanish population. In addition to know the epidemiological picture,&#xD;
      it is intended to study the nutritional status from different points of view: analytical,&#xD;
      clinical, anthropometric, etc. Besides, the study of nutritional status will allow us to&#xD;
      closely monitor the patients who have a higher risk of malnutrition and to propose early&#xD;
      interventions for those, as well as the impact of their nutritional status on different&#xD;
      parameters: survival, hospitalization, quality of life or responses to the treatments.&#xD;
&#xD;
      NUTRIGETNE is a cross-sectional, open and multicenter study in which the nutritional status&#xD;
      of patients with GEP NET in Spain will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NUTRIGETNE is a cross-sectional, open and multicenter study in which the nutritional status&#xD;
      of patients with GEP NET in Spain will be evaluated. It is planned to include 400 GEP NET&#xD;
      patients. Patients will be included consecutively when visiting the corresponding health&#xD;
      centers for outpatient visits or hospitalization.&#xD;
&#xD;
      The study comprises 3 stages with a total duration of 10 to 40 days for the participation of&#xD;
      each subject in the study:&#xD;
&#xD;
      Screening visit, First day (day 0): The initial screening will take place on the first day&#xD;
      the patient visits the hospital. The inclusion and exclusion criteria will be reviewed to&#xD;
      assess the eligibility of the patient. The implications of the study will be explained to the&#xD;
      patient and the informed consent will be signed.&#xD;
&#xD;
      Visit for assessment of nutritional status (days 0-10): taking a medical history, complete&#xD;
      physical examination including anthropometry, bioelectrical impedance (BIA) and dynamometry,&#xD;
      as well as laboratory analysis. The evaluation of the nutritional status will be carried out&#xD;
      by a registered nutritionist, specialized nurse or specialist doctor (variable depending on&#xD;
      the characteristics of the center).&#xD;
&#xD;
      Data collection (day 10-40): collection of analytical, anthropometric, BIA, dynamometry and&#xD;
      clinical results and introduction into the electronic case report form (eCRF).&#xD;
&#xD;
      After the end of recruitment and database lock, all data will be subsequently analyzed and&#xD;
      presented when applicable through study reports and scientific communications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 24, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of malnutrition in GEP NET</measure>
    <time_frame>Throughout the study period. Nutritional status will be reported at a single timepoint for each patient (between 1-10 days after informed consent signature)</time_frame>
    <description>Percentage of GEP NET patients suffering from malnutrition in Spain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk of malnutrition in GEP NET</measure>
    <time_frame>Throughout the study period. Nutritional status will be reported at a single timepoint for each patient (between 1-10 days after informed consent signature)</time_frame>
    <description>Percentage of GEP NET patients at risk of suffering from malnutrition in Spain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body mass index</measure>
    <time_frame>Throughout the study period. Nutritional status will be reported at a single timepoint for each patient (between 1-10 days after informed consent signature)</time_frame>
    <description>Body mass index (BMI) is defined as a a measure of body fat based on height and weight that applies to adult men and women</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat</measure>
    <time_frame>Throughout the study period. Nutritional status will be reported at a single timepoint for each patient (between 1-10 days after informed consent signature)</time_frame>
    <description>Body fat mass calculated by bioimpedance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body muscle mass</measure>
    <time_frame>Throughout the study period. Nutritional status will be reported at a single timepoint for each patient (between 1-10 days after informed consent signature)</time_frame>
    <description>Body muscle mass calculated by bioimpedance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional Risk Screening (NRS) rates</measure>
    <time_frame>Throughout the study period. Nutritional status will be reported at a single timepoint for each patient (between 1-10 days after informed consent signature)</time_frame>
    <description>Scale to evaluate the malnutrition in adult patients. It is based in the assessment of BMI, weight loss in the last 3-6 months and acute disease effects. The score ranges from 0 (low malnutrition risk to 6 (high malnutrition risk).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Global Assessment (SGA) rates</measure>
    <time_frame>Throughout the study period. Nutritional status will be reported at a single timepoint for each patient (between 1-10 days after informed consent signature)</time_frame>
    <description>Score to measure risk malnutrition in adult patients based on patient history and physical examination alone. The score has 3 levels: A (low malnutrition risk) to C (high malnutrition risk)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Gastroenteropancreatic Neuroendocrine Tumor</condition>
  <arm_group>
    <arm_group_label>GEP NET</arm_group_label>
    <description>GEP NET patients in Spain</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with gastroenteropancreatic neuroendocrine tumors diagnosed histologically&#xD;
        that are on active treatment for the disease in Spain&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with a gastroenteropancreatic neuroendocrine tumor by&#xD;
             histopathological study.&#xD;
&#xD;
          -  Legally capable patients ≥ 18 and ≤ 80 years of age.&#xD;
&#xD;
          -  Patients who have signed the informed consent for this study as specified in section&#xD;
             10.3.&#xD;
&#xD;
          -  Patients in active treatment: active treatment is considered to be those patients in&#xD;
             an advanced stage and in any type of medical treatment (somatostatin analogues,&#xD;
             molecular therapies, chemotherapy, radionuclides...), or locoregional therapies.&#xD;
&#xD;
        Note: Decision was taken to treat the patient with an specific treatment prior and&#xD;
        independently of patient inclusion in this non interventional study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients &lt;18 or &gt; 80 years of age.&#xD;
&#xD;
          -  Female patients that are currently pregnant.&#xD;
&#xD;
          -  Patients with a gastroenteropancreatic neuroendocrine tumor lacking an&#xD;
             histopathological diagnosis.&#xD;
&#xD;
          -  Patients in palliative treatment or terminal stage.&#xD;
&#xD;
          -  Patients who have not signed the informed consent or any situation or condition that&#xD;
             compromises the giving of patient voluntary informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>María Isabel del Olmo García, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Fe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>María Argente Pla, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Fe</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d´Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Josep Trueta</name>
      <address>
        <city>Gerona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Cabueñes</name>
      <address>
        <city>Gijón</city>
        <zip>33394</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Poliècnic la Fe</name>
      <address>
        <city>Valencia</city>
        <zip>40026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Valencià d'Oncologia (IVO)</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GEP NET</keyword>
  <keyword>Neuroendocrine tumor</keyword>
  <keyword>Nutritional status</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

